Karlovy Vary 1

This research aims to evaluate how well and safely orforglipron works in adult female participants with stress urinary incontinence SUI who also have obesity or are overweight. SUI is a condition where urine leaks during activities such as coughing or exercising. The study is a Phase 3 clinical trial conducted under a master protocol supporting two independent studies, focusing on this specific population. Participants will be randomly assigned to receive either orforglipron or a placebo, both given orally once daily. The study uses a double-blind design with parallel groups to compare the effects of orforglipron against placebo. The treatment period lasts approximately 52 weeks, followed by safety follow-up, making total participation about 58 weeks from screening to study completion. During the study, participants will undergo assessments including measuring changes in the frequency of incontinence episodes, body weight, quality of life related to urinary incontinence, use of continence pads, and cholesterol levels. Researchers will monitor waist circumference and patient impressions of their condition as well. Safety follow-up continues after treatment to ensure participant well-being throughout the study duration.

Hidradenitis suppurativa HS is a painful inflammatory skin condition affecting areas like the underarms, groin, and genital regions. This trial evaluates the safety and effectiveness of upadacitinib, an oral drug approved for other inflammatory diseases, in adults and adolescents with moderate to severe HS who have not responded well or cannot tolerate anti-TNF therapies. The study is double-blinded and involves multiple treatment periods to assess disease activity and side effects. Participants will take oral tablets of either upadacitinib or a placebo once daily during the first two periods, each lasting 36 weeks. In Period 1, participants are randomly assigned to receive either upadacitinib or placebo. Period 2 assigns participants to one of six groups based on their response in Period 1, with treatment continuing for 20 weeks. In Period 3, eligible participants continue their assigned treatment for an additional 68 weeks, followed by a 30-day follow-up. Throughout the study, participants will attend regular outpatient visits where medical assessments will monitor treatment effects and side effects. Questionnaires and clinical evaluations will be completed to measure changes in disease activity and quality of life. The trial aims to track the percentage of participants achieving clinical response and the occurrence of adverse events over the entire study duration, which may be longer than standard care treatments.

Researchers are conducting a national, prospective, multicenter, non-interventional pilot project to screen for Hepatitis C virus HCV infection among people who inject drugs PWID in the Czech Republic. The main goal is to prepare, implement, and assess a method for early detection of Hepatitis C and to develop new procedures for integrating this screening into social health care systems. This project aims to help prevent further transmission of the virus by improving early diagnosis and care continuity.

Overactive bladder OAB is a common health issue affecting 15-20% of adults, but less than half seek medical help. This research aims to raise awareness of OAB and improve referrals to specialists who can provide appropriate diagnosis and treatment. The project is led by the Institute of Health Information and Statistics of the Czech Republic and focuses on early detection and reducing the negative impact of OAB on quality of life. The study uses an online screening tool available via a web platform and mobile app, where participants complete validated questionnaires related to OAB symptoms, personal and family history, and quality of life. Those with positive screening results are offered an examination by specialists such as gynecologists, urogynaecologists, or urologists. Specialists access participant profiles through the platform, confirm or rule out OAB, perform additional diagnostic tests if needed, and set up standard treatments. Participation requires consent to data processing under GDPR. Participants will provide data through the online tool and may attend follow-up examinations with specialists. The study tracks outcomes including the number of participants completing the screening, those agreeing to specialist visits, confirmed diagnoses, and follow-up attendance over an average period of six to nine months. Data collected will evaluate the pilot projects effectiveness and cost, with all information stored securely respecting privacy regulations.